CBP-1018 for advanced cancers that no standard treatment helped
Part of Cancer clinical trials.
This early-phase study tests CBP-1018 in people with advanced solid tumors, such as prostate, kidney, or certain lung cancers. It aims to see how the drug works and whether it’s safe enough to continue studying.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign informed consent before any study steps.
- Your cancer is an advanced solid tumor (examples include mCRPC, kidney cancer, or lung squamous cancer) that has either had standard treatment or you likely can’t benefit from it.
- You’re well enough to do daily activities (ECOG “performance status” 0–1) and your life expectancy is at least 3 months.
- You have at least one measurable tumor spot on scans (or, for prostate cancer only, an eligible bone-related finding).
- Your blood counts and organs (bone marrow, liver, kidneys) meet safety thresholds for starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CBP-1019 combined with chemotherapy (FOLFOX) and possibly other drugs for people with advanced solid tumors that have stopped responding to standard treatments. It may be an option if you have a type of cancer that hasn't gotten better with other therapies.
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
This early-phase trial tests an experimental drug called ICP-B794 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and begins to show signs of shrinking tumors.
This Phase 1 study tests CBP-1008, a new experimental treatment, in people with advanced solid cancers that either worsened after standard treatment or for which no standard option exists. It may help doctors learn the safest dose and whether it shows signs of benefit in specific tumor types.
This trial tests an experimental pill called ABP1011T for people with advanced solid tumors that are no longer responding to standard treatments. It is especially focused on small cell lung cancer and other cancers that might be sensitive to this drug. The goal is to see if the pill can shrink tumors or slow their growth.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.